Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump — ANGELA WEISS/AFP via Getty Images via Getty Images

Drug Prices · United States

Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump

50% Center coverage: 322 sources

Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.See the Story

After FDA exit, Peter Marks pops up at Lilly

Robert F. Kennedy Jr. · Indianapolis

After FDA exit, Peter Marks pops up at Lilly

40% Right coverage: 10 sources

The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.See the Story

New Drug Approved for Deadly Lung Condition, First in Over a Decade

United States · United States

New Drug Approved for Deadly Lung Condition, First in Over a Decade

100% Center coverage: 4 sources

(MedPage Today) -- The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday. Primary support for the preferential...See the Story

Breaking News Topics Related to biopharmadive.com